P2Y12 Inhibitor Management in STEMI Patients Treated with Fibrinolysis

Initial Management and P2Y12 Inhibitor Selection

The European Society of Cardiology recommends clopidogrel as the initial P2Y12 inhibitor for STEMI patients receiving fibrinolytic therapy, administered in addition to aspirin as soon as possible (Class I, Level A recommendation) 1, 2, 3, 4
Clopidogrel is specifically indicated for STEMI patients receiving thrombolytic therapy, distinguishing it from the primary PCI setting where potent P2Y12 inhibitors are preferred (Class I, Level A recommendation) 1, 2, 3, 4
The ESC guidelines explicitly state that clopidogrel is indicated in addition to aspirin when fibrinolysis is the reperfusion strategy, without recommending prasugrel or ticagrelor in this specific context 1, 2, 3, 4

Administer clopidogrel as soon as possible when initiating fibrinolytic therapy, ideally in the pre-hospital setting along with aspirin and the fibrin-specific thrombolytic agent 1, 2
Oral or IV aspirin should be given concurrently (Class I, Level B) 1, 2, 3

All patients treated with fibrinolysis should be transferred to a PCI-capable center immediately after thrombolytic administration (Class I, Level A) 1, 2, 4
Angiography and PCI of the infarct-related artery should be performed between 2-24 hours after successful fibrinolysis (Class I, Level A) 1, 2, 4
At the time of PCI, transition to a potent P2Y12 inhibitor (prasugrel or ticagrelor) is recommended and should be maintained for 12 months unless contraindications exist 5, 2

Perform rescue PCI immediately when fibrinolysis has failed or with hemodynamic/electrical instability (Class I, Level A) 1, 2, 4
Transition from clopidogrel to prasugrel or ticagrelor at the time of rescue PCI 5
Emergency angiography and PCI are recommended for patients developing heart failure/shock after fibrinolysis (Class I, Level A) 1, 2, 4
Emergency PCI is indicated for recurrent ischemia or evidence of reocclusion after initial successful fibrinolysis (Class I, Level B) 1, 2, 4

Continue dual antiplatelet therapy (aspirin plus P2Y12 inhibitor) for 12 months after PCI, whether performed as routine post-lysis angiography or rescue/emergency PCI (Class I, Level A) 5, 2

Anticoagulation is mandatory in patients treated with lytics until revascularization or for the duration of hospital stay up to 8 days 1, 2, 3
Enoxaparin IV followed by subcutaneous is preferred over unfractionated heparin (Class I, Level A) 1, 2, 3
Alternatively, weight-adjusted UFH IV bolus followed by infusion is acceptable (Class I, Level B) 1, 2, 3

Do not use prasugrel or ticagrelor as the initial P2Y12 inhibitor with fibrinolytic therapy—the evidence base and guideline recommendations specifically support clopidogrel in this setting 1, 2, 3, 4
Do not delay transfer to a PCI-capable center after fibrinolysis—all patients require angiography regardless of apparent lysis success (Class I, Level A) 1, 2, 4
Do not continue clopidogrel after PCI is performed—escalate to prasugrel or ticagrelor at the time of coronary intervention for optimal outcomes 5
Do not miss the 2-24 hour window for routine angiography after successful fibrinolysis—this timing is evidence-based and improves outcomes (Class I, Level A) 1, 2, 4